Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-15 19:58:26 EDT

PhotosVideosAllPeople
LatestRanked
@onc-rg.bsky.socialOct 2, 2026, 12:07 AM

π™π™π™š 2026 π™€π™Žπ™ˆπ™Š π™‡π˜½π˜Ό π™‡π™–π™£π™™π™¨π™˜π™–π™₯π™š: π™‘π™žπ™¨π™ͺπ™–π™‘π™žπ™―π™šπ™™.
Which mechanisms are commanding the late-breaker spotlight this year?

#ESMO2026 #ESMO26 #Oncology #NSCLC #SCLC #ADCs #vaccines #ClinicalData #DrugTrials #CompetitiveStrategy

Our analysts crunched the numbers across all LBAs: βœ”οΈADCs lead the field β€” nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond βœ”οΈCheckpoint inhibition isn't just a category β€” it's still the default combo partner, showing up alongside ADCs, vaccines, PARP inhibitors and more βœ”οΈBeyond PD-(L)1 and the usual ADC targets (HER2, TROP-2, B7-H3), RAS/KRAS momentum is continuing from ASCO Stay ahead of the competitive curve with verified insights. Our analysts crunched the numbers across all LBAs: βœ”οΈADCs lead the field β€” nearly a third of all LBA drugs, spanning NSCLC, breast, ovarian, and beyond βœ”οΈCheckpoint inhibition isn't just a category β€” it's still the default combo partner, showing up alongside ADCs, vaccines, PARP inhibitors and more βœ”οΈBeyond PD-(L)1 and the usual ADC targets (HER2, TROP-2, B7-H3), RAS/KRAS momentum is continuing from ASCO Stay ahead of the competitive curve with verified insights.
@passback.bsky.socialSep 14, 2026, 10:08 PM

at $8–12 CPM, while a premium spot runs many times that.
Start around $50.
Clear viewability reporting.

PassBack: start around $50. $8–12 CPM. No contracts. We nail competitive TV strategy. passback.tv

#PassbackCTV #TVAds #StreamingAds #MarketingStrategy #CompetitiveStrategy #MediaBuying